Production (Stage)
Chemomab Therapeutics Ltd.
CMMB
$1.23
$0.032.50%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | 58.69% | -71.49% |
| Total Depreciation and Amortization | -- | -- | -- | 14.29% | 23.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -67.84% | -44.62% |
| Change in Net Operating Assets | -- | -- | -- | -130.52% | 110.87% |
| Cash from Operations | -- | -- | -- | 34.82% | -93.64% |
| Capital Expenditure | -- | -- | -- | 100.00% | 92.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -81.56% | 502.38% |
| Cash from Investing | -- | -- | -- | -81.56% | 505.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 511.17% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 345.45% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | -94.96% | 645.22% |